Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TENAX THERAPEUTICS, INC. entered into Warrant Agency Agreement with Direct Transfer LLC (effective 2024-02-12).
- Action
- entry
- Counterparty
- Direct Transfer LLC
- Effective
- 2024-02-12
Exact text from the filing
On February 12, 2024, the Company also entered into a warrant agency agreement (the “Warrant Agency Agreement”) with the Company’s transfer agent, Direct Transfer LLC, who will act as warrant agent for the Company, setting forth the terms and conditions of the Common Warrants.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TENAX THERAPEUTICS, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at gross proceeds of approximately $9.0 million (effective 2024-02-08).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Roth Capital Partners, LLC
- Value
- gross proceeds of approximately $9.0 million
- Effective
- 2024-02-08
Exact text from the filing
On February 8, 2024, Tenax Therapeutics, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TENAX THERAPEUTICS, INC. entered into Purchase Agreement with certain purchasers valued at gross proceeds of approximately $9.0 million (effective 2024-02-08).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain purchasers
- Value
- gross proceeds of approximately $9.0 million
- Effective
- 2024-02-08
Exact text from the filing
On February 8, 2024, Tenax Therapeutics, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers
View on SEC.gov